{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:54:15Z","timestamp":1770350055395,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.vaccine.2022.03.056","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T11:58:16Z","timestamp":1648641496000},"page":"2705-2713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial"],"prefix":"10.1016","volume":"40","author":[{"given":"Jessica W.","family":"Crothers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Ross Colgate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy M.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MaryClaire","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marya","family":"Carmolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter F.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth D.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.03.056_b0005","doi-asserted-by":"crossref","unstructured":"Rutter PD, Hinman AR, Hegg L, King D, Sosler S, Swezy V, et al., Transition Planning For After Polio Eradication. J Infect Dis 2017;216:S287\u201392.","DOI":"10.1093\/infdis\/jix026"},{"key":"10.1016\/j.vaccine.2022.03.056_b0010","doi-asserted-by":"crossref","unstructured":"WHO. World Health Organization Weekly Epidemiological Record. Polio Vaccines: WHO Position Paper-March 2016. In: World Health Organization Weekly Epidemiological Record. Polio Vaccines: WHO Position Paper-March 2016. https:\/\/www.who.int\/wer\/2016\/wer9112.pdf?ua=1.","DOI":"10.1016\/j.vaccine.2016.11.017"},{"key":"10.1016\/j.vaccine.2022.03.056_b0015","unstructured":"Organization WH Africa eradicates wild poliovirus. In: Africa eradicates wild poliovirus. https:\/\/www.afro.who.int\/news\/africa-eradicates-wild-poliovirus."},{"issue":"6","key":"10.1016\/j.vaccine.2022.03.056_b0020","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/infdis\/162.6.1291","article-title":"Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses","volume":"162","author":"Faden","year":"1990","journal-title":"J Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.vaccine.2022.03.056_b0025","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.vaccine.2022.03.056_b0030","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","article-title":"Vaccine-derived polioviruses","volume":"210","author":"Burns","year":"2014","journal-title":"J Infect Dis"},{"issue":"16","key":"10.1016\/j.vaccine.2022.03.056_b0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.15585\/mmwr.mm6916a1","article-title":"Update on Vaccine-Derived Poliovirus Outbreaks \u2014 Worldwide, July 2019\u2013February 2020","volume":"69","author":"Alleman","year":"2020","journal-title":"Morbidity Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.03.056_b0040","doi-asserted-by":"crossref","unstructured":"Rubin J, Ottosen A, Ghazieh A, Fournier-Caruana J, Ntow AK, Gonzalez AR. Managing the Planned Cessation of a Global Supply Market: Lessons Learned From the Global Cessation of the Trivalent Oral Poliovirus Vaccine Market. J Infect Dis 2017;216:S40\u20135.","DOI":"10.1093\/infdis\/jiw571"},{"issue":"9953","key":"10.1016\/j.vaccine.2022.03.056_b0045","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(14)60934-X","article-title":"Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial","volume":"384","author":"John","year":"2014","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"10.1016\/j.vaccine.2022.03.056_b0050","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S1473-3099(16)30169-4","article-title":"Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants","volume":"16","author":"Wright","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"6199","key":"10.1016\/j.vaccine.2022.03.056_b0055","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1126\/science.1255006","article-title":"Efficacy of inactivated poliovirus vaccine in India","volume":"345","author":"Jafari","year":"2014","journal-title":"Science"},{"issue":"10040","key":"10.1016\/j.vaccine.2022.03.056_b0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","article-title":"Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial","volume":"388","author":"Asturias","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2022.03.056_b0065","doi-asserted-by":"crossref","unstructured":"Gamage D, Mach O, Palihawadana P, Zhang Y, Weldon WC, Oberste MS, et al. Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine. J Infect Dis 2018;218:1876\u201382.","DOI":"10.1093\/infdis\/jiy389"},{"key":"10.1016\/j.vaccine.2022.03.056_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002599","article-title":"Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge","volume":"8","author":"Hird","year":"2012","journal-title":"Plos Pathog"},{"key":"10.1016\/j.vaccine.2022.03.056_b0075","first-page":"5011","article-title":"Koopmans MP (1999) Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus","volume":"162","author":"Herremans","year":"1950","journal-title":"J Immunol Baltim Md"},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.056_b0080","doi-asserted-by":"crossref","first-page":"e2002468","DOI":"10.1371\/journal.pbio.2002468","article-title":"Assessing the stability of polio eradication after the withdrawal of oral polio vaccine","volume":"16","author":"Famulare","year":"2018","journal-title":"Plos Biol"},{"key":"10.1016\/j.vaccine.2022.03.056_b0085","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1093\/infdis\/jix108","article-title":"Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.056_b0090","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CVI.00538-10","article-title":"Characterization of a mutant escherichia coli heat-labile Toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant","volume":"18","author":"Norton","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.056_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00215-18","article-title":"The Mucosal Vaccine Adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"issue":"16","key":"10.1016\/j.vaccine.2022.03.056_b0100","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.03.056_b0105","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.4161\/hv.32253","article-title":"Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system","volume":"10","author":"White","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"39","key":"10.1016\/j.vaccine.2022.03.056_b0110","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1016\/j.vaccine.2021.08.032","article-title":"Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli","volume":"39","author":"Lee","year":"2021","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.03.056_b0115","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1128\/CVI.00464-13","article-title":"Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli","volume":"20","author":"El-Kamary","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.056_b0120","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.vaccine.2018.12.011","article-title":"A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G\/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.03.056_b0125","article-title":"Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants","author":"Svennerholm","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.03.056_b0130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/mi.2017.70","article-title":"Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4+ T cells following parenteral immunization","volume":"11","author":"Frederick","year":"2018","journal-title":"Mucosal Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2022.03.056_b0135","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00460-19","article-title":"Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA\/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli","volume":"87","author":"Maciel","year":"2019","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2022.03.056_b0140","doi-asserted-by":"crossref","first-page":"e0224073","DOI":"10.1371\/journal.pone.0224073","article-title":"Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G\/L211A) by intradermal immunization in mice","volume":"14","author":"Maciel","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2022.03.056_b0145","doi-asserted-by":"crossref","unstructured":"Lewis I, Ottosen A, Rubin J, Blanc DC, Zipursky S, Wootton E., A Supply and demand management perspective on the accelerated global introductions of inactivated poliovirus vaccine in a constrained supply market. J Infect Dis 2017;216:S33\u20139.","DOI":"10.1093\/infdis\/jiw550"},{"key":"10.1016\/j.vaccine.2022.03.056_b0150","doi-asserted-by":"crossref","unstructured":"Okayasu H, Sein C, Blanc DC, Gonzalez AR, Zehrung D, Jarrahian C, et al., Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization. J Infect Dis 2017;216:S161\u20137.","DOI":"10.1093\/infdis\/jix038"},{"issue":"11","key":"10.1016\/j.vaccine.2022.03.056_b0155","doi-asserted-by":"crossref","first-page":"e0224073","DOI":"10.1371\/journal.pone.0224073","article-title":"Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G\/L211A) by intradermal immunization in mice","volume":"14","author":"Maciel","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2022.03.056_b0160","doi-asserted-by":"crossref","unstructured":"Javier Mart\u00edn (Ed.), Poliovirus: Methods and Protocols, Methods in Molecular Biology, vol. 1387, DOI https:\/\/doi.org\/10.1007\/978-1-4939-3292-4_8, \u00a9 Springer Science+Business Media New York 2016.","DOI":"10.1007\/978-1-4939-3292-4"},{"key":"10.1016\/j.vaccine.2022.03.056_b0165","doi-asserted-by":"crossref","unstructured":"Wright PF, Wieland-Alter W, Ilyushina NA, et al., Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis 2014;209:1628\u201334.","DOI":"10.1093\/infdis\/jit671"},{"issue":"10193","key":"10.1016\/j.vaccine.2022.03.056_b0170","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"Lancet"},{"issue":"10268","key":"10.1016\/j.vaccine.2022.03.056_b0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(20)32541-1","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials","volume":"397","author":"De Coster","year":"2021","journal-title":"Lancet"},{"issue":"10268","key":"10.1016\/j.vaccine.2022.03.056_b0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials","volume":"397","author":"S\u00e1ez-Llorens","year":"2021","journal-title":"Lancet"},{"issue":"8763","key":"10.1016\/j.vaccine.2022.03.056_b0190","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0140-6736(91)90480-D","article-title":"Immune response to intradermally injected inactivated poliovirus vaccine","volume":"338","author":"Samuel","year":"1991","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2022.03.056_b0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0264-410X(92)90039-M","article-title":"Immune response of infants to inactivated poliovirus vaccine injected intradermally","volume":"10","author":"Samuel","year":"1992","journal-title":"Vaccine"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2022.03.056_b0200","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0264-410X(97)00293-4","article-title":"Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine","volume":"16","author":"Nirmal","year":"1998","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.03.056_b0205","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-3083.2010.02416.x","article-title":"Intradermal delivery of recombinant vaccinia virus vector DIs induces gutmucosal immunity","volume":"72","author":"Yoshino","year":"2010","journal-title":"Scand J Immunol"},{"issue":"24","key":"10.1016\/j.vaccine.2022.03.056_b0210","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/S0264-410X(00)00059-1","article-title":"The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity","volume":"18","author":"Enioutina","year":"2000","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.03.056_b0215","doi-asserted-by":"crossref","first-page":"e100879","DOI":"10.1371\/journal.pone.0100879","article-title":"Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01","volume":"9","author":"Dietrich","year":"2014","journal-title":"PLoS One"},{"issue":"52","key":"10.1016\/j.vaccine.2022.03.056_b0220","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.vaccine.2014.10.069","article-title":"Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study","volume":"32","author":"Lundgren","year":"2014","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2022.03.056_b0225","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.15585\/mmwr.mm6845a4","article-title":"Update on Vaccine-Derived Poliovirus Outbreaks \u2014 Worldwide, January 2018\u2013June 2019","volume":"68","author":"Jorba","year":"2019","journal-title":"Mmwr Morbidity Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.03.056_b0230","doi-asserted-by":"crossref","unstructured":"Brickley EB, Strauch CB, Wieland-Alter WF, et al., Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. J Infect Dis 2018;217:371\u201380.","DOI":"10.1093\/infdis\/jix556"},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.056_b0235","doi-asserted-by":"crossref","first-page":"e001613","DOI":"10.1136\/bmjgh-2019-001613","article-title":"Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden","volume":"4","author":"Brickley","year":"2019","journal-title":"Bmj Global Heal"},{"issue":"2","key":"10.1016\/j.vaccine.2022.03.056_b0240","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41385-018-0110-8","article-title":"Microanatomical dissection of human intestinal T-cell immunity reveals site-specific changes in gut-associated lymphoid tissues over life","volume":"12","author":"Senda","year":"2019","journal-title":"Mucosal Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.03.056_b0245","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm.4008","article-title":"Early-life compartmentalization of human T cell differentiation and regulatory function in mucosal and lymphoid tissues","volume":"22","author":"Thome","year":"2016","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.03.056_b0250","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/pr.2011.26","article-title":"Neonatal T-cell maturation and homing receptor responses to Toll-like receptor ligands differ from those of adult naive T cells: relationship to prematurity","volume":"71","author":"Crespo","year":"2012","journal-title":"Pediatr Res"},{"issue":"1","key":"10.1016\/j.vaccine.2022.03.056_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41385-021-00428-0","article-title":"Mucosal immunity to poliovirus","volume":"15","author":"Connor","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2022.03.056_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.puhe.2020.09.004","article-title":"Delays in polio vaccination programs due to COVID-19 in Pakistan: a major threat to Pakistan\u2019s long war against polio virus","volume":"189","author":"Din","year":"2020","journal-title":"Public Health"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2022.05.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200367X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200367X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:20:27Z","timestamp":1653870027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2200367X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":51,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0264410X2200367X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}